Article
Review. Molecular background of chemoresistance in pancreatic cancer.
In vivo (Athens, Greece) - 1 Jan 2000
Zalatnai Attila, Molnár József
Abstract excerpt
The survival data of patients with ductal pancreatic adenocarcinoma are rather poor, partly because the disease is frequently diagnosed at an advanced stage, partly because it is characterized by a chemoresistant phenotype. Even first-line chemotherapeutic drugs result in a modest objective response. This drug resistance is attributed to many different, unrelated mechanisms, including abnormal membrane receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
